CYRX
Cryoport, Inc.
NASDAQ · Industrials · Integrated Freight & Logistics · US
$15.81
−0.32%Aug 6, 2026, 20:05 UTC
Cryoport reported its second quarter 2026 financial results, with revenue growing 8% year-over-year to $49.0 million and Life Sciences Services revenue up 15%, BioStorage/BioServices revenue up 25%, supporting 779 global clinical trials and 22 commercially approved cell and gene therapies as of June 30, 2026.
Jun 25, 2026, 12:00 UTC
Cryoport's IntegriCell cryopreservation services were selected by Verismo Therapeutics to support its clinical KIR-CAR T cell therapy programs.
Source: